Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1985 Sep;61(3):548–555.

Subsets of T lymphocytes in relation to T lymphocyte function in multiple sclerosis.

J C Craig, S A Hawkins, M W Swallow, J A Lyttle, V H Patterson, J D Merrett, M Haire
PMCID: PMC1577275  PMID: 3000660

Abstract

T lymphocyte control of Epstein-Barr virus (EBV) infection of autologous B lymphocytes was examined in parallel to the enumeration of subpopulations of mononuclear cells in 22 multiple sclerosis (MS) patients and in 22 healthy individuals. All were seropositive for EBV. The incidence of lack of T cell control was significantly higher in patients than in controls, confirming previous published work. In the present study, we have shown in addition a significantly reduced proportion of OKT8+ cells and a significantly increased ratio of OKT4/OKT8 cells in the group of patients with lack of control. The findings point to abnormal immunoregulation in MS.

Full text

PDF
548

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alspaugh M. A., Henle G., Lennette E. T., Henle W. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest. 1981 Apr;67(4):1134–1140. doi: 10.1172/JCI110127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antel J. P., Arnason B. G., Medof M. E. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol. 1979 Apr;5(4):338–342. doi: 10.1002/ana.410050406. [DOI] [PubMed] [Google Scholar]
  3. Arnason B. G. Abnormalities of immunocyte function in multiple sclerosis. Acta Neuropathol Suppl. 1983;9:7–20. doi: 10.1007/978-3-642-69094-5_2. [DOI] [PubMed] [Google Scholar]
  4. Bach M. A., Phan-Dinh-Tuy F., Tournier E., Chatenoud L., Bach J. F., Martin C., Degos J. D. Deficit of suppressor T cells in active multiple sclerosis. Lancet. 1980 Dec 6;2(8206):1221–1223. doi: 10.1016/s0140-6736(80)92480-0. [DOI] [PubMed] [Google Scholar]
  5. Benczur M., Petrányl G. G., Pálffy G., Varga M., Tálas M., Kotsy B., Földes I., Hollán S. R. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol. 1980 Mar;39(3):657–662. [PMC free article] [PubMed] [Google Scholar]
  6. Brinkman C. J., Nillesen W. M., Hommes O. R. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide. Clin Immunol Immunopathol. 1983 Dec;29(3):341–348. doi: 10.1016/0090-1229(83)90037-5. [DOI] [PubMed] [Google Scholar]
  7. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  8. Compston A. Lymphocyte subpopulations in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1983 Feb;46(2):105–114. doi: 10.1136/jnnp.46.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Compston D. A., Hughes P. J. Peripheral blood lymphocyte sub-populations and multiple sclerosis. J Neuroimmunol. 1984 Apr;6(2):105–114. doi: 10.1016/0165-5728(84)90031-6. [DOI] [PubMed] [Google Scholar]
  10. Duke O., Panayi G. S., Janossy G., Poulter L. W., Tidman N. Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis. 1983 Aug;42(4):357–361. doi: 10.1136/ard.42.4.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gaston J. S., Rickinson A. B., Epstein M. A. Epstein-Barr virus-specific cytotoxic T cell responses in rheumatoid arthritis patients. Rheumatol Int. 1982;2(4):155–159. doi: 10.1007/BF00286137. [DOI] [PubMed] [Google Scholar]
  12. Gonzalez R. L., Dau P. C., Spitler L. E. Altered regulation of mitogen responsiveness by suppressor cells in multiple sclerosis. Clin Exp Immunol. 1979 Apr;36(1):78–84. [PMC free article] [PubMed] [Google Scholar]
  13. Goust J. M., Hoffman P. M., Pryjma J., Hogan E. L., Fudenberg H. H. Defective immunoregulation in multiple sclerosis. Ann Neurol. 1980 Nov;8(5):526–533. doi: 10.1002/ana.410080510. [DOI] [PubMed] [Google Scholar]
  14. Haire M. Significance of virus antibodies in multiple sclerosis. Br Med Bull. 1977 Jan;33(1):40–44. doi: 10.1093/oxfordjournals.bmb.a071394. [DOI] [PubMed] [Google Scholar]
  15. Hasler F., Bluestein H. G., Zvaifler N. J., Epstein L. B. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation. J Exp Med. 1983 Jan 1;157(1):173–188. doi: 10.1084/jem.157.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hauser S. L., Ault K. A., Levin M. J., Garovoy M. R., Weiner H. L. Natural killer cell activity in multiple sclerosis. J Immunol. 1981 Sep;127(3):1114–1117. [PubMed] [Google Scholar]
  17. Hauser S. L., Reinherz E. L., Hoban C. J., Schlossman S. F., Weiner H. L. Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period. Ann Neurol. 1983 Apr;13(4):418–425. doi: 10.1002/ana.410130408. [DOI] [PubMed] [Google Scholar]
  18. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Iivanainen M. V. The significance of abnormal immune responses in patients with multiple sclerosis. J Neuroimmunol. 1981 Jun;1(2):141–172. doi: 10.1016/0165-5728(81)90040-0. [DOI] [PubMed] [Google Scholar]
  20. Johnson G. D., Nogueira Araujo G. M. A simple method of reducing the fading of immunofluorescence during microscopy. J Immunol Methods. 1981;43(3):349–350. doi: 10.1016/0022-1759(81)90183-6. [DOI] [PubMed] [Google Scholar]
  21. Merrill J. E., Mohlstrom C., Uittenbogaart C., Kermaniarab V., Ellison G. W., Myers L. W. Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J Immunol. 1984 Oct;133(4):1931–1937. [PubMed] [Google Scholar]
  22. Merrill J., Jondal M., Seeley J., Ullberg M., Sidén A. Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity in the disease. Clin Exp Immunol. 1982 Feb;47(2):419–430. [PMC free article] [PubMed] [Google Scholar]
  23. Miller G., Lipman M. Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus. J Exp Med. 1973 Dec 1;138(6):1398–1412. doi: 10.1084/jem.138.6.1398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  25. Morimoto C., Distaso J. A., Cheney J. J., Reinherz E. L., Schlossman S. F. Cellular interaction between subsets of T8 population for maximal suppression of antigen-specific antibody response. Cell Immunol. 1984 Oct 1;88(1):75–84. doi: 10.1016/0008-8749(84)90053-4. [DOI] [PubMed] [Google Scholar]
  26. Moss D. J., Pope J. H. Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972 Nov;17(2):233–236. doi: 10.1099/0022-1317-17-2-233. [DOI] [PubMed] [Google Scholar]
  27. Moss D. J., Rickinson A. B., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer. 1978 Dec;22(6):662–668. doi: 10.1002/ijc.2910220604. [DOI] [PubMed] [Google Scholar]
  28. Neighbour P. A., Bloom B. R. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci U S A. 1979 Jan;76(1):476–480. doi: 10.1073/pnas.76.1.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Neighbour P. A., Grayzel A. I., Miller A. E. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol. 1982 Jul;49(1):11–21. [PMC free article] [PubMed] [Google Scholar]
  30. Neighbour P. A., Miller A. E., Bloom B. R. Interferon responses of leukocytes in multiple sclerosis. Neurology. 1981 May;31(5):561–566. doi: 10.1212/wnl.31.5.561. [DOI] [PubMed] [Google Scholar]
  31. Paty D. W., Kastrukoff L., Morgan N., Hiob L. Suppressor T-lymphocytes in multiple sclerosis: analysis of patients with acute relapsing and chronic progressive disease. Ann Neurol. 1983 Oct;14(4):445–449. doi: 10.1002/ana.410140408. [DOI] [PubMed] [Google Scholar]
  32. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  33. Reinherz E. L., Weiner H. L., Hauser S. L., Cohen J. A., Distaso J. A., Schlossman S. F. Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med. 1980 Jul 17;303(3):125–129. doi: 10.1056/NEJM198007173030303. [DOI] [PubMed] [Google Scholar]
  34. Rice G. P., Finney D., Braheny S. L., Knobler R. L., Sipe J. C., Oldstone M. B. Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8. J Neuroimmunol. 1984 Apr;6(2):75–84. doi: 10.1016/0165-5728(84)90028-6. [DOI] [PubMed] [Google Scholar]
  35. Rickinson A. B., Rowe M., Hart I. J., Yao Q. Y., Henderson L. E., Rabin H., Epstein M. A. T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol. 1984 Sep;87(2):646–658. doi: 10.1016/0008-8749(84)90032-7. [DOI] [PubMed] [Google Scholar]
  36. Rickinson A. B. T-cell control of herpesvirus infections: lessons from the Epstein-Barr virus. Prog Brain Res. 1983;59:189–202. doi: 10.1016/S0079-6123(08)63864-9. [DOI] [PubMed] [Google Scholar]
  37. Sakane T., Takada S., Murakawa Y., Kotani H., Honda M., Ueda Y. Analysis of suppressor T cell function in patients with rheumatoid arthritis: defects in production of and responsiveness to concanavalin A-induced suppressor T cells. J Immunol. 1982 Nov;129(5):1972–1977. [PubMed] [Google Scholar]
  38. Salonen R., Ilonen J., Reunanen M., Salmi A. Defective production of interferon-alpha associated with HLA-DW2 antigen in stable multiple sclerosis. J Neurol Sci. 1982 Aug;55(2):197–206. doi: 10.1016/0022-510x(82)90101-0. [DOI] [PubMed] [Google Scholar]
  39. Sandberg-Wollheim M. Lymphocyte populations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis and optic neuritis. Scand J Immunol. 1983 Jun;17(6):575–581. doi: 10.1111/j.1365-3083.1983.tb00826.x. [DOI] [PubMed] [Google Scholar]
  40. Seitz M., Deimann W., Gram N., Hunstein W., Gemsa D. Characterization of blood mononuclear cells of rheumatoid arthritis patients. I. Depressed lymphocyte proliferation and enhanced prostanoid release from monocytes. Clin Immunol Immunopathol. 1982 Dec;25(3):405–416. doi: 10.1016/0090-1229(82)90205-7. [DOI] [PubMed] [Google Scholar]
  41. Shirodaria P. V., Fraser K. B., Armstrong M., Roberts S. D. Measles virus-specific antibodies and immunoglobulin M antiglobulin in sera from multiple sclerosis and rheumatoid arthritis patients. Infect Immun. 1979 Jul;25(1):408–416. doi: 10.1128/iai.25.1.408-416.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stöger I., Tálas M., Benczúr M., Gyódi E., Petrányi G. G., Pálffy G., Kotsy B. Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis. Arch Virol. 1982;71(3):259–265. doi: 10.1007/BF01314877. [DOI] [PubMed] [Google Scholar]
  43. Tjernlund U., Cesaro P., Tournier E., Degos J. D., Bach J. F., Bach M. A. T-cell subsets in multiple sclerosis: a comparative study between cell surface antigens and function. Clin Immunol Immunopathol. 1984 Aug;32(2):185–197. doi: 10.1016/0090-1229(84)90120-x. [DOI] [PubMed] [Google Scholar]
  44. Vervliet G., Claeys H., Van Haver H., Carton H., Vermylen C., Meulepas E., Billiau A. Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients. J Neurol Sci. 1983 Jul;60(1):137–150. doi: 10.1016/0022-510x(83)90133-8. [DOI] [PubMed] [Google Scholar]
  45. Weiner H. L., Hafler D. A., Fallis R. J., Johnson D., Ault K. A., Hauser S. L. Altered blood T-cell subsets in patients with multiple sclerosis. J Neuroimmunol. 1984 Apr;6(2):115–121. doi: 10.1016/0165-5728(84)90032-8. [DOI] [PubMed] [Google Scholar]
  46. Weiner H. L., Hauser S. L. Neuroimmunology I: Immunoregulation in neurological disease. Ann Neurol. 1982 May;11(5):437–449. doi: 10.1002/ana.410110502. [DOI] [PubMed] [Google Scholar]
  47. Yam L. T., Li C. Y., Crosby W. H. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol. 1971 Mar;55(3):283–290. doi: 10.1093/ajcp/55.3.283. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES